Researcher
Yentl Van Rymenant
- Keywords:Pharmacy and pharmacology
- Disciplines:Analytical biochemistry, Biomarker discovery, Biomarker evaluation, Protein diagnostics
Affiliations
- Medical Biochemistry (Research group)
Member
From8 Jun 2024 → Today - Medical Biochemistry (Research group)
Member
From1 Nov 2019 → 7 Jun 2024 - Medical Biochemistry (Research group)
Member
From15 Aug 2019 → 31 Oct 2019
Projects
1 - 1 of 1
- Development of tools and methods for the evaluation of FAP as a predictive/prognostic biomarker in cancer.From1 Nov 2019 → 31 Oct 2023Funding: FWO Strategic Basic Research Grant
Publications
1 - 10 of 10
- Druglike, ¹⁸F-labeled PET tracers targeting fibroblast activation protein (FAP)(2024)
Authors: Muhammet Tanc, Nicolò Filippi, Yentl Van Rymenant, Sergei Grintsevich, Isabel Pintelon, Marlies Verschuuren, Joni De Loose, Emile Verhulst, Euy Sung Moon, Lorenzo Cianni, et al.
Pages: 7068 - 7087 - Active site-directed probes targeting dipeptidyl peptidases 8 and 9(2024)
Authors: Margarida Florindo Espadinha, Joni De Loose, Sam Corthaut, Sofie Thys, Yentl Van Rymenant, Emile Verhulst, Siham Benramdane, Nicolò Filippi, Koen Augustyns, Pieter Van Wielendaele, et al.
Pages: 1 - 12 - Intercellular interaction between FAP+ fibroblasts and CD150+ inflammatory monocytes mediates fibro-stenosis in Crohn’s disease(2024)
Authors: Bo-Jun Ke, Saeed Abdurahiman, Francesca Biscu, Gaia Zanella, Gabriele Dragoni, Sneha Santhosh, Veronica De Simone, Anissa Zouzaf, Lies van Baarle, Michelle Stakenborg, et al.
- Next generation fibroblast activation protein (FAP) targeting PET tracers: the tetrazine ligation allows an easy and convenient way to ¹⁸F-labeled (4-quinolinoyl)glycyl-2-cyanopyrrolidines(2023)
Authors: Christian B.M. Poulie, Vladimir Shalgunov, Filipe Elvas, Yentl Van Rymenant, Euy-Sung Moon, Umberto Maria Battisti, Joni De Loose, Ingrid De Meester, Frank Rösch, Pieter Van Der Veken, et al.
Pages: 1 - 10 - Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics(2023)
Authors: Marcel Martin, Sanjana Ballal, Madhav Prasad Yadav, Chandrasekhar Bal, Yentl Van Rymenant, Joni De Loose, Emile Verhulst, Ingrid De Meester, Pieter Van Der Veken, Frank Roesch
Pages: 1 - 25 - Highly selective inhibitors of dipeptidyl peptidase 9 (DPP9) derived from the clinically used DPP4-inhibitor vildagliptin(2023)
Authors: Siham Benramdane, Joni De Loose, Nicolò Filippi, Margarida Florindo Espadinha, Olivier Beyens, Yentl Van Rymenant, Laura Dirkx, Murat Bozdag, Koen Augustyns, Guy Caljon, et al.
Pages: 12717 - 12738 - Vildagliptin‐derived dipeptidyl peptidase 9 (DPP9) inhibitors: identification of a DPP8/9‐specific lead(2022)
Authors: Siham Benramdane, Joni De Loose, Olivier Beyens, Yentl Van Rymenant, Gwendolyn Vliegen, Koen Augustyns, Hans De Winter, Ingrid De Meester, Pieter Van Der Veken
Pages: 1 - 16 - In vitro evaluation of the squaramide-conjugated fibroblast activation protein inhibitor-based agents AAZTA5.SA.FAPi and DOTA.SA.FAPi(2021)
Authors: Euy Sung Moon, Yentl Van Rymenant, Sandeep Battan, Joni De Loose, An Bracke, Pieter Van Der Veken, Ingrid De Meester, Frank Rösch
- In vitro and in situ activity-based labeling of fibroblast activation protein with UAMC1110-derived probes(2021)
Authors: Yentl Van Rymenant, Muhammet Tanc, Roos Van Elzen, An Bracke, Olivier De Wever, Koen Augustyns, Anne-Marie Lambeir, Mark M. Kockx, Ingrid De Meester, Pieter Van Der Veken
- Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time(2021)
Authors: Euy Sung Moon, Sanjana Ballal, Madhav Prasad Yadav, Chandrasekhar Bal, Yentl Van Rymenant, Sarah Stephan, An Bracke, Pieter Van Der Veken, Ingrid De Meester, Frank Roesch
Pages: 476 - +
Patents
1 - 1 of 1
- Inhibitors of fibroblast activation protein (Inventor)